Trending News Today: Philadelphia Considers Safe Injection Sites Amidst Opioid Epidemic

Yesterday, Democrats questioned Alex Azar, President Donald Trump’s pick for Secretary of Health and Human Services, about how he plans to lower high drug costs, according to Kaiser Health News. Azar told the Senate Finance Committee that he was ready to fix the poorly structured health care system and tackle prescription drug spending. Although Democrats pointed to increased costs under his leadership at Eli Lilly, Azar said that the supply chain encourages drug companies to up their prices, which is a problem he plans to address if confirmed, according to the article.

Senate Democrats are calling for an additional $25 billion to be included in a final budget bill to address the opioid epidemic, The Hill reported. The lawmakers argue that budget negotiations can be leveraged to remedy what has thus far been an inadequate federal response to the epidemic, according to the article. Top Democrats have previously pushed for funding, but it has yet to be included in any short- or long-term spending deals.

Philadelphia officials are advocating for the implementation of supervised injection sites in light of a boom in injection drug use related to the opioid epidemic, according to NPR. The safe injection sites would provide clean needles and equipment, as well as medical supervision in hopes of increasing treatment and mitigating potential new infections with HIV or hepatitis C virus. The controversial proposal must overcome resistance from police officials, city residents, and the government, according to the article.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.
Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.
Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.